Retatrutide 20mg
Triple Agonist GLP-1 + GIP + Glucagon (LY3437943)
4 mechanisms. One peptide.
What this peptide does at the cellular level, in plain words.
GLP-1 activation
First of the three receptors. Satiety and glycemic control.
GIP activation
Second receptor. Synergizes with GLP-1 to amplify metabolic effect.
Glucagon activation
Third receptor. Increases energy expenditure and fat oxidation.
Triple agonist
Phase II reports: up to 24.2% weight reduction in 48 weeks. Category record.
Stacks. What to pair it with.
Peptides often synergize. These are the most studied combinations with this product, and what outcome they target.
CJC-1295 + Ipa
Aggressive recomp
Preserves lean mass during extreme caloric deficit.
BPC-157
GI tolerance
Reduces gastrointestinal discomfort from triple agonism.
GHK-Cu
Dramatic change + skin
Big losses need skin support. GHK-Cu provides it.
Any combination must respect each peptide's protocol. If you have doubts about dosing or timing, message us before starting.
Technical description
Retatrutide (also known as LY3437943) is the first triple agonist peptide in the GLP-1 class, simultaneously targeting GLP-1, GIP, and glucagon receptors through a single molecule. Currently in Phase III clinical trials by Eli Lilly under the TRIUMPH program, retatrutide represents the frontier of metabolic peptide research.
SuperBio Labs Retatrutide is provided as lyophilized powder, ≥99% pure by HPLC, with full LC-MS sequence confirmation. Each batch is supplied with an independent Certificate of Analysis covering purity, peptide content (98–102%), endotoxin levels (<1.0 EU/mg), and residual solvents.
The triple agonist mechanism distinguishes retatrutide from single (semaglutide) and dual (tirzepatide) agonists: simultaneous glucagon receptor activation increases energy expenditure and lipolysis, while GLP-1 + GIP signaling produces appetite reduction and insulin sensitization. In Phase II trials, retatrutide demonstrated up to 24.2% body weight reduction at 48 weeks, the highest reported for any GLP-1 class molecule.
For Research Use Only.
Your complete kit, ready to apply.
We don't just hand you the vial. Every Retatrutide purchase includes everything you need to apply it safely, with a clear protocol and our team available 24/7.
Retatrutide vial
Lyophilized · HPLC purity ≥99% · Batch with COA
Bacteriostatic water 30ml
Sterile diluent · 0.9% benzyl alcohol
1 extraction syringe 3ml
21G needle · For peptide reconstitution
5–10 insulin syringes (29G)
10mg → 5 · 20mg → 10 · 1×/week
10–20 alcohol wipes 70%
10mg → 10 · 20mg → 20 · 2 per application (vial + skin)
Printed protocol
Physical document · Reconstitution and dosing
Visual step-by-step guide
8 steps · From opening the kit to application
SuperBio OS · Support
App · Tracking · Human team 24/7
About supplies: the quantity of syringes and wipes adjusts automatically based on the presentation you choose. For extended cycles (BPC-157, GHK-Cu and similar) we cap supplies at 30 days — beyond that, 29G insulin syringes and 70% alcohol wipes are pharmacy items available without prescription in any city.
Recommended application protocol.
This is the conservative protocol included in the kit. We send it printed and digital, along with your access to SuperBio OS for tracking and support. If you have pre-existing medical conditions, consult a professional before starting.
Recommended titration
Wk 1–2: 2mg → Wk 3–4: 4mg → Wk 5–8: 6mg → Wk 9–16: 8–12mg
Triple agonist GLP-1 + GIP + glucagon. Frontier molecule.
Technical specifications
| Product | Retatrutide |
| CAS Number | 2381089-83-2 |
| Molecular Weight | 4731 Da |
| Purity (HPLC) | ≥99% |
| Format | Lyophilized powder |
| Quantity | 20mg per vial |
| Endotoxin | <1.0 EU/mg |
| Storage | −20 °C, protected from light |
| Use | Research Use Only (RUO) |